Microba Life Sciences Limited

Equities

MAP

AU0000209868

Healthcare Facilities & Services

Market Closed - Australian S.E. 01:33:47 2024-06-14 am EDT 5-day change 1st Jan Change
0.175 AUD 0.00% Intraday chart for Microba Life Sciences Limited -2.78% -2.78%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Microba's Revenue Climbs 297% in Fiscal Q3 MT
Microba Life Sciences Secures AU$6 Million Tax Rebate for Fiscal Year 2023; Shares Fall 5% MT
2,700,000 Options of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-APR-2024. CI
48,031,314 Ordinary Shares of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-APR-2024. CI
Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data MT
Microba Life Sciences Rise 9% Following Launch of MetaPanel Test With Sonic Healthcare MT
Microba Life Sciences Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
8,250,000 Options of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 5-FEB-2024. CI
54,500,297 Ordinary Shares of Microba Life Sciences Limited are subject to a Lock-Up Agreement Ending on 27-JAN-2024. CI
Weak Oil Prices, China's Property Woes Hold Down Australian Shares MT
Microba Life Sciences Validates Safety, Tolerability of Inflammatory Bowel Disease Therapy in Phase One Trial MT
Microba Life Sciences Completes Acquisition of UK Microbiome Testing Company; Shares Slide 5% MT
Microba Life Sciences Limited completed the acquisition of Invivo Clinical Limited. CI
Microba Life Sciences Signs Research Agreement with IFF Subsidiary to Develop Allergy Treatments MT
Microba Life Sciences' Domestica, International Personal Testing Revenue Rises in Fiscal Q1 MT
Microba Life Sciences to Acquire Invivo Clinical MT
Microba Life Sciences Limited signed a binding share purchase agreement to acquire Invivo Clinical Limited for £11 million. CI
Microba Life Sciences Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Microba Life Sciences Completes Dosing for Phase One Trial of Biotherapeutic Product MT
Microba Life Sciences Signs Commercial Agreement with Sonic Healthcare for MetaPanel; Shares Jump 7% MT
Microba Life Sciences Limited Executes Commercial Agreement with Sonic Healthcare Limited CI
Microba Life Sciences Doses First Participants for Phase One Trial MT
Microba Life Sciences Secures Grant Funding for Biobank Program MT
Microba Life Sciences Limited Announces $2.92 Million Grant Award to QUT, in Collaboration with Microba to Develop a Human Microbiome Biobank CI
Microba Life Sciences Limited Receives Approval of Two Further R&D Tax Incentive Advanced Overseas Findings CI
Chart Microba Life Sciences Limited
More charts
Microba Life Sciences Limited is an Australia-based precision microbiome company. The Company is engaged in the discovery and development of therapeutics for major chronic diseases and delivers gut microbiome testing services globally to researchers, clinicians, and consumers. It offers various platforms, such as Analysis, Discovery, and Therapeutic. Through its analysis and discovery platforms, it identifies microbiome-derived therapeutics and diagnostic tools to advance medicine. Through its Analysis Platform, it generates a global databank of microbiome samples and associated metadata to develop new health solutions. Its Discovery Platform enables partners to access this databank for the data-driven discovery of product opportunities. Its therapeutic platform is a repeatable platform for microbial therapeutic leads. It also offers a product portfolio of gastrointestinal, vaginal, oral, and urinary microbiome testing, together with a targeted set of evidence-based formulations.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.175 AUD
Average target price
0.38 AUD
Spread / Average Target
+117.14%
Consensus

Quarterly revenue - Rate of surprise